Testing a new injection for inherited high cholesterol
Part of Heart & circulation clinical trials.
This study tests a new injection called ART002g1 for people with an inherited form of high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if it is safe and can help lower cholesterol levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your weight must be between 45 and 90 kg (about 99 to 198 pounds).
- You must have a confirmed diagnosis of heterozygous familial hypercholesterolemia (HeFH) — this can be through a genetic test or by having very high cholesterol and other signs like skin/tendon deposits or a family history of early heart disease.
- You cannot have the more severe forms of familial hypercholesterolemia (homozygous or compound forms).
- You must not have had a recent heart attack, stroke, heart failure, or heart procedures (like angioplasty or bypass) in the last 6 months.
- You must not have active hepatitis B, C, or HIV infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called YOLT-101 for people with familial hypercholesterolemia, a genetic condition that causes very high cholesterol. The treatment aims to lower cholesterol levels and reduce heart risks.
This study tests an investigational medicine called QLC7401 for people with a genetic condition called heterozygous familial hypercholesterolemia, which causes very high cholesterol. It aims to see if the new medicine can further lower bad cholesterol when added to your usual cholesterol treatments.
This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.
This trial tests a one-time gene therapy to lower extremely high cholesterol in people with a rare inherited condition. It may help reduce heart attack risk in those who haven't responded to standard treatments.
This study tests a new injection called SYH2053 for people with HeFH, a genetic condition that causes very high cholesterol. It looks at whether the injection can safely lower LDL cholesterol when added to standard statin therapy.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
Hear when a new Heterozygous Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.